CY1108275T1 - Χημικες ενωσεις - Google Patents

Χημικες ενωσεις

Info

Publication number
CY1108275T1
CY1108275T1 CY20081100887T CY081100887T CY1108275T1 CY 1108275 T1 CY1108275 T1 CY 1108275T1 CY 20081100887 T CY20081100887 T CY 20081100887T CY 081100887 T CY081100887 T CY 081100887T CY 1108275 T1 CY1108275 T1 CY 1108275T1
Authority
CY
Cyprus
Prior art keywords
chemical compounds
novel compounds
cancer
formula
treatment
Prior art date
Application number
CY20081100887T
Other languages
English (en)
Inventor
Michelle Lamb
Peter Mohr
Bin Wang
Tao Wang
Dingwei Yu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1108275T1 publication Critical patent/CY1108275T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Αυτή η εφεύρεση αναφέρεται σε νέες ενώσεις του τύπου (Ι)· και στις φαρμακευτικές τους συνθέσεις και τις μεθόδους χρήσης τους. Αυτές οι νέες ενώσεις παρέχουν μία θεραπεία για τον καρκίνο.
CY20081100887T 2005-02-16 2008-08-21 Χημικες ενωσεις CY1108275T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65357505P 2005-02-16 2005-02-16
US74213805P 2005-12-01 2005-12-01
EP06709750A EP1853588B1 (en) 2005-02-16 2006-02-15 Chemical compounds

Publications (1)

Publication Number Publication Date
CY1108275T1 true CY1108275T1 (el) 2014-02-12

Family

ID=36168456

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100887T CY1108275T1 (el) 2005-02-16 2008-08-21 Χημικες ενωσεις

Country Status (22)

Country Link
US (2) US8129403B2 (el)
EP (1) EP1853588B1 (el)
JP (1) JP5001179B2 (el)
KR (1) KR101362621B1 (el)
AT (1) ATE398613T1 (el)
AU (1) AU2006215386B2 (el)
BR (1) BRPI0607455A2 (el)
CA (1) CA2597813C (el)
CY (1) CY1108275T1 (el)
DE (1) DE602006001515D1 (el)
DK (1) DK1853588T3 (el)
ES (1) ES2308731T3 (el)
HK (1) HK1114375A1 (el)
IL (1) IL185063A (el)
MX (1) MX2007009843A (el)
NO (1) NO20073788L (el)
NZ (1) NZ561525A (el)
PL (1) PL1853588T3 (el)
PT (1) PT1853588E (el)
RU (1) RU2405780C2 (el)
SI (1) SI1853588T1 (el)
WO (1) WO2006087530A1 (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
HUE025671T2 (en) * 2005-02-04 2016-04-28 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
MX2007014328A (es) * 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
AU2007309468B2 (en) * 2006-10-19 2012-05-17 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
RU2009118963A (ru) * 2006-10-20 2010-11-27 Н.В. Органон (Nl) Пурины в качестве ингибиторов ркс-тета
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
GB0725218D0 (en) * 2007-12-24 2008-02-06 Syngenta Ltd Chemical compounds
AR072085A1 (es) * 2008-06-11 2010-08-04 Astrazeneca Ab Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas
AU2009299599A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic JAK kinase inhibitors
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
ES2894958T3 (es) 2011-10-19 2022-02-16 Signal Pharm Llc Tratamiento del cáncer con inhibidores de la quinasa TOR
KR102040997B1 (ko) 2011-12-02 2019-11-27 시그날 파마소티칼 엘엘씨 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
EP2861231B1 (en) 2012-06-14 2016-08-31 Eli Lilly and Company Inhibitor of jak1 and jak2
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP3202403A1 (en) 2013-01-16 2017-08-09 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
AU2014224975B2 (en) * 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
JP2016510764A (ja) 2013-03-07 2016-04-11 カリフィア バイオ, インク.Califia Bio, Inc. 混合系キナーゼ阻害剤および治療法
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
KR20160002792A (ko) 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CN105324381A (zh) 2013-04-17 2016-02-10 西格诺药品有限公司 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
TWI656875B (zh) 2013-04-17 2019-04-21 美商標誌製藥公司 藉二氫吡并吡治療癌症
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
TWI663159B (zh) * 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US9623028B2 (en) 2014-07-14 2017-04-18 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
TWI696621B (zh) 2014-12-18 2020-06-21 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
UA118312C2 (uk) 2014-12-23 2018-12-26 Ексікін Фармасутікалз, Інк. 3,5-діамінопіразолові інгібітори кінази
WO2018237114A1 (en) 2017-06-22 2018-12-27 Celgene Corporation TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
US5006116A (en) 1988-12-21 1991-04-09 Kimberly-Clark Corporation Tampon with single layer powder bonded wrap
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1998044341A1 (de) 1997-03-27 1998-10-08 Glatt Gmbh Verfahren zum überwachen und/oder steuern und regeln eines granulations-, agglomerations-, instantisierungs-, coating- und trocknungsprozesses in einer wirbelschicht oder einer bewegten schüttung durch bestimmung der produktfeuchte sowie lufttechnischer apparat zur durchführung des verfahrens
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
US6247246B1 (en) 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
AU5583099A (en) 1998-09-03 2000-03-27 Malcam Ltd. Moisture measurement device using microwaves
US6227041B1 (en) 1998-09-17 2001-05-08 Cem Corporation Method and apparatus for measuring volatile content
CA2350801C (en) 1998-11-10 2008-05-20 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
HU228449B1 (en) 1999-09-24 2013-03-28 Janssen Pharmaceutica Nv Antiviral compositions
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
EP1242385B1 (en) 1999-12-28 2009-11-25 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2407754C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
EE200300085A (et) 2000-08-31 2004-12-15 Pfizer Products Inc. Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
AU8664701A (en) 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105947B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なトリアゾール化合物
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6875789B2 (en) 2001-08-03 2005-04-05 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
AU2002321910A1 (en) 2001-08-03 2003-02-17 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
DE60215682T2 (de) 2001-09-27 2007-09-06 Smithkline Beecham Corp. AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
US6747461B2 (en) 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
JP2007052466A (ja) 2003-11-17 2007-03-01 Nec Corp 画像処理方法、画像処理システム、および画像処理プログラム
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
AU2005228904C1 (en) 2004-03-30 2012-12-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
JP2007533717A (ja) 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
WO2006052913A1 (en) 2004-11-04 2006-05-18 Vertex Pharmaceuticals Incorporated PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES
DE102004053734B4 (de) 2004-11-06 2007-01-18 Sartorius Ag Trocknungswaage
HUE025671T2 (en) 2005-02-04 2016-04-28 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CA2598076A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
JP2008540335A (ja) 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
EP1876178B1 (en) 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
EP1888561A1 (en) 2005-05-05 2008-02-20 AstraZeneca AB Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
MX2007014328A (es) 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
JP5328361B2 (ja) 2005-11-03 2013-10-30 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
EP2044063A1 (en) 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
TW200823196A (en) 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) 2006-11-01 2008-07-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
HK1114375A1 (en) 2008-10-31
IL185063A0 (en) 2007-12-03
EP1853588A1 (en) 2007-11-14
US20080176872A1 (en) 2008-07-24
PL1853588T3 (pl) 2008-11-28
WO2006087530A1 (en) 2006-08-24
KR101362621B1 (ko) 2014-02-13
JP5001179B2 (ja) 2012-08-15
BRPI0607455A2 (pt) 2009-09-01
CA2597813A1 (en) 2006-08-24
JP2008530190A (ja) 2008-08-07
DK1853588T3 (da) 2008-09-15
CA2597813C (en) 2014-04-22
NO20073788L (no) 2007-09-03
PT1853588E (pt) 2008-08-25
AU2006215386A1 (en) 2006-08-24
ES2308731T3 (es) 2008-12-01
MX2007009843A (es) 2007-08-23
RU2007134396A (ru) 2009-03-27
US20120122892A1 (en) 2012-05-17
EP1853588B1 (en) 2008-06-18
KR20070103773A (ko) 2007-10-24
US8129403B2 (en) 2012-03-06
AU2006215386B2 (en) 2009-06-11
DE602006001515D1 (de) 2008-07-31
IL185063A (en) 2012-01-31
RU2405780C2 (ru) 2010-12-10
SI1853588T1 (sl) 2008-10-31
NZ561525A (en) 2010-11-26
ATE398613T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA200970156A1 (ru) Пиридизиноновые производные
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
MY153915A (en) Organic compounds
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA200801997A1 (ru) Новые соединения
TW200738659A (en) Novel compounds
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
EA201170344A1 (ru) Азаиндольные ингибиторы iap
SG158091A1 (en) Imidazoazepinone compounds
TW200621260A (en) Selected fused heterocyclics and uses thereof
TW200745133A (en) New compounds II
ATE474574T1 (de) Imidazoazephinonverbindungen
EA200870157A1 (ru) Производные 2-карбамид-4-фенилтиазола, их получение и их применение в терапии
EA200702590A1 (ru) Ингибиторы растворимой аденилатциклазы